The device will be commercialized by R2 Dermatology, a Blossom Innovations company. Founded in 2014 by Pansend Life Sciences, a subsidiary of HC2 Holdings and Blossom Innovations, R2 Dermatology recently entered into an agreement granting exclusive distribution rights to Huadong Medicine Company Limited for R2’s products in the Asia-Pacific. Huadong is leading the latest round of equity investment in R2 Dermatology.

“As innovators, it is exceptionally rewarding when one of our technologies progresses towards global commercialization,” said Irina Erenburg, Ph.D., co-founder, president, & CEO of Blossom Innovations. “We are thrilled to have R2 Dermatology work with Huadong Medicine to help us enter the largest market for skin lightening medical devices.”

Blossom Innovations addresses challenging clinical conditions primarily in the area of dermatology through the combined effort of their founders – an innovation team of the most respected researchers and clinicians in dermatology. From white board inception to clinical feasibility, Blossom invents revolutionary medical device technology platforms that are then transferred for product development and commercialization.

This latest device was created by scientists R. Rox Anderson, M.D., director of the Wellman Center at Massachusetts General Hospital, a teaching affiliate of Harvard Medical School – Department of Dermatology; Dieter Manstein, M.D., Ph.D., Department of Dermatology at Massachusetts General Hospital; and Henry H.L. Chan, M.D., Ph.D., Department of Medicine, The University of Hong Kong and the visiting scientist of the Wellman Center, Massachusetts General Hospital.

“Advances in the understanding of fundamental biology and skin response to controlled, precision cooling have allowed us to create a technology platform that modulates cellular response without harming underlying tissue,” added R. Rox Anderson, M.D., co-founder of Blossom Innovations.

“The new cold-based medical device technology platform provides a safe and comfortable patient experience, offers predictable outcomes, and requires no patient downtime,” said Henry H.L. Chan, M.D., Ph.D., co-founder and chairman of Blossom’s board. “We look forward to future regulatory submission in Asia, most importantly in China, where there is a significant unmet clinical need.”

Source: Company Press Release